Changing therapeutic landscape - The last decade

Transfusion and Apheresis Science

Volumn 44, Issue 2, 2011, Pages 155-159

  Aurer, Igor ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ASPARAGINASE; BENDAMUSTINE; BORTEZOMIB; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; LENALIDOMIDE; METHOTREXATE; PRALATREXATE; PREDNISONE; RITUXIMAB; ROMIDEPSIN; TEMSIROLIMUS; THALIDOMIDE; VINCRISTINE; VORINOSTAT;

ARTICLE; BONE MARROW SUPPRESSION; BRAIN LYMPHOMA; BURKITT LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG TARGETING; FOLLICULAR LYMPHOMA; GRANULOCYTOPENIA; HODGKIN DISEASE; HUMAN; IMMUNE DEFICIENCY; IMMUNOGLOBULIN DEFICIENCY; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; PERIPHERAL T CELL LYMPHOMA; PROGNOSIS; RADIOIMMUNOTHERAPY; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG THERAPY; HUMANS; IMMUNOTHERAPY; LYMPHOMA; MEDICAL ONCOLOGY; NITROGEN MUSTARD COMPOUNDS; PREDNISOLONE; PROTEASOME ENDOPEPTIDASE COMPLEX; RADIOIMMUNOTHERAPY; TREATMENT OUTCOME; VINCRISTINE;

EID: 79952619086     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transci.2011.01.010     Document Type: Article

References (49)

1. Cvetkovic R.S., Perry C.M. Rituximab - a review of its use in Non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2006, 66:791-820.
2. Feugier P., Van Hoof A., Sebban C., et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005, 23:4117-4126.
3. Pfreundschuh M., Truemper L., Oesterborg A., et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006, 7:379-391.
4. Habermann T.M., Weller E.A., Morrison V.A., et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006, 24:3121-3127.
5. Sehn L.H., Donaldson J., Chhanabhai M., et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005, 23:5027-5033.
6. Marcus R., Imrie K., Belch A., et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005, 105:1417-1423.
7. Hiddemann W., Kneba M., Dreyling M., et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005, 106:3725-3732.
8. Herold M., Haas A., Srock S., et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007, 25:1986-1992.
9. Salles G.A., Foussard C., Nicolas M., et al. Rituximab added to αIFN+CHVP improves the outcome of follicular lymphoma patients with a high tumor burden: first analysis of the GELA-GOELAM FL-2000 randomized trial in 359 patients. Blood 2004, 104:49a.
10. Schulz H., Bohlius J.F., Trelle S., et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Nat Cancer Inst 2007, 99:706-714.
11. Glennie M.J., French R.R., Cragg M.S., Taylor R.P. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007, 44:3823-3837.
12. Hagenbeek A., Lewington V. Report of a European consensus workshop to develop recommendations for the optimal use of 90Y-ibritumomab tiuxetan (Zevalin®) in lymphoma. Ann Oncol 2005, 16:786-792.
13. Press O.W., Unger J.M., Braziel R.M., et al. Phase II trial of CHOP chemotherapy followid by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwes Oncology Group Protocol S9911. J Clin Oncol 2006, 24:4143-4149.
14. Lundin J., Porwitt-MacDonald A., Rossmann E.D., et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukemia. Leukemia 2004, 18:484-490.
15. Kalaycio M. Bendamustine: a new look at an old drug. Cancer 2009, 115:473-479.
16. Schmitz N., Nickelsen M., Ziepert M., et al. Aggressive chemotherapy (CHOEP-14) and rituximab or high-dose therapy (MegaCHOEP) and rituximab for young, high-risk patients with aggressive B-cell lymphoma: results of the MegaCHOEP trial of the German High-Grade non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 2009, 114:168a. (abstr. 404).
17. Delarue R., Tilly H., Salles G., et al. R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma: results of the interim analysis of the LNH03-6B GELA study. Blood 2009, 114:169a. (abstr. 406).
18. Vellenga E., vanPutten W.L.J., van't Veer M.B., Zijlstra J.M., Fibbe W.E., van Oers M.H.J., et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood 2008, 111:537-543.
19. Gisselbrecht C., Glass B., Mounier N., et al. R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study. J Clin Oncol 2009, 27:15. (abstr. 8509).
20. Reyes F., Lepage E., Ganem G., et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 2005, 352:1197-1205.
21. Pfreundschuh M., Ziepert M., Reiser M., et al. The role of radiotherapy to bulky disease in the rituximab era: results from two prospective trials of the German High-Grade Non-Hodgkin-Lymphoma Study Group (DSHNHL) for elderly patients with DLBCL. Blood 2008, 112:219. (abstr. 584).
22. Zinzani P.L., Fina M., Tani M., et al. A phase II trial of rituximab-CHOP chemotherapy followed by yttrium 90 (90Y) ibritumomab tiuxetan (90Y-IT) for previously untreated elderly diffuse large B-cell lymphoma (DLBCL) patients. Blood 2009, 114:1065. (abstr. 2720).
23. vanKampen R., Canals C., Schouten H., et al. Allogeneic stem cell transplantation as salvage therapy in patients with diffuse large B-cell noin-Hodgkin's lymphoma relapsing after an autologous stem cell transplantation. An analysis of the EBMT registry. Bone Marrow Transpl 2009, 43(Suppl. 1):S36. (abstr. O255).
24. Geisler C.H., Kolstad A., Laurell A., et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line chemotherapy with in vivo-purged stem cell rescue: a nonrandomize phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008, 112:2687-2693.
25. Kaufmann H., Raderer M., Wohrer S., et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 2004, 104:2269-2271.
26. Habermann T.M., Lossos I.S., Justice G., et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 2009, 145:344-349.
27. O'Connor O.A., Moskowitz C., Portlock C., et al. Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicenre phase 2 clinical trial. Br J Haematol 2009, 145:34-39.
28. Hess G., Herbrecht R., Romaguera J., et al. Phase III study to evaluate temsirolimus compared with investigaotr's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009, 27:3822-3829.
29. Swerdlow S.H., Campo E., Harris N.L., et al. WHO classification of tumours of hematopoietic and lymphoid tissues 2008, IARC, Lyon.
30. Nickelsen M., Ziepert M., Zeynalova S., et al. High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade non-Hodgkin Lymphoma Study Group (DSHNHL). Ann Oncol 2009, 20:1977-1984.
31. D'Amore F., Relander T., Lauritzen G.F., et al. Dose-dense induction followed by autologous stem cell transplant (ASCT) leads to sustained remissions in a large fraction of patients with previously untreated peripheral T-cell lymphomas (PTCLs) - overall and subtype-specific results of a phase II study from the Nordic Lymphoma Group. Haematologica 2009, 94(s2):43. (abstr. 1082).
32. Jaccard A., Suarez F., Thieblemont C., et al. l-asparaginase in the treatment of extranodal NK/T-cell lymphoma. Ann Oncol 2008, 19(Suppl. 4):156. (abstr. 243).
33. O'Connor O.A., Horwitz S., Hamlin P., et al. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol 2009, 27:4357-4364.
34. Olsen E.A., Kim Y.H., Kuzel T.M., et al. Phase IIB multicenter trial of vorinostat in pateints with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007, 25:3109-3115.
35. Piekarz R.L., Frye R., Turner M., et al. Phase II multi-insitutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009, 27:5410-5417.
36. Hoelzer D. Recent results in the treatment of Burkitt lymphomas. Ann Oncol 2008, 19(Suppl. 4):8. (abstr. 8).
37. Dunleavy K., Little R.F., Pittaluga S., et al. A prospective study of dose-adjusted (DA) EPOCH with rituximab in adults with newly diagnosed Burkitt lymphoma: a regimen with high efficacy and low toxicity. Ann Oncol 2008, 19(Suppl. 4):83-84. (abstr. 9).
38. Rummel M.J., Niederle N., Maschmeyer G., et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood 2009, 114:168a-169a. (abstr. 405).
39. van Oers M.H.J., Klasa R., Marcus R.E. I sur. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006, 108:3295-3301.
40. Forstpointer R., Unterhalt M., Dreyling M. i sur. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006, 108:4003-4008.
41. Brugger W. Clearing minimal residual disease with rituximab consolidation therapy. Semin Oncol 2004, 31(Suppl. 2):33-37.
42. Morschhauser F., Radford J., vanHoof A. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008, 26:556-564.
43. Husain A., Roberts D., Pro B., et al. Meta-analyses of the association between Chlamydia psittaci and ocular adnexal lymphoma and the response of ocular adnexal lymphoma to antibiotics. Cancer 2007, 110:809-815.
44. Hancock B., Linch D., Delchier J., et al. Chlorambucil versus observation after anti-Helicobacter therapy in low-grade gastric lymphoma: results of the international LY03 trial. Ann Oncol 2005, 16(Suppl. 5):57.
45. Ferreri A.J., Foppoli M., Martelli M., et al. Randomized phase II trial on primary chemotherapy (CHT) with high-dose methotrexate (MTX) alone or associated with high-dose cytarabine (ARAC) for patients (pts) with primary CNS lymphoma (PCNSL). Ann Oncol 2008, 19(Suppl. 4):104. (abstr. 065).
46. Engert A., Diehl V., Pluetschow A., et al. Two cycles of ABVD followed by involved field radiotherapy with 20 Gray (Gy) is the new standard of care in the treatment of patients with early-stage Hodgkin lymphoma: final analysis of the randomized German Hodgkin Study Group (GHSG) H10. Blood 2009, 114:299a. (abstr. 716).
47. Diehl V., Franklin J., Pfreundschuh M., et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003, 348:2386-2395.
48. Validire P., Ferme C., Brice P., et al. A multicenter study of gemcitabine-containing regimen in relapsed or refractory Hodgkin's lymphoma patients. Anti-Cancer Drugs 2008, 19:309-315.
49. Meyer R.M., Gospodarowicz M.K., Connors J.M., et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005, 23:4634-4642.